2 results
Approved WMOCompleted
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
Approved WMOCompleted
Primary Objective: To compare the pharmacokinetics of the needlefree system with the Apo-go penject. Secondary objectives: - To assess the clinical effect of Apo-go vs. de needlefree system, using an "automated tap score" and a "Timed…